Clinical implications of serum <i>N‐</i>glycan profiling as a diagnostic and prognostic biomarker in germ‐cell tumors
Takuma Narita(Hirosaki University), Chikara Οhyama(Hirosaki University), Hayato Yamamoto(Hirosaki University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Yuki Tobisawa(Hirosaki University), Shigeyuki Nakaji(Hirosaki University), Shintaro Narita(Akita University), Shinichi Yamashita, Takuya Koie(Hirosaki University), Ippei Takahashi(Hiroshima University), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Tohru Yoneyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Shingo Hatakeyama(Hirosaki University), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Tomonori Habuchi(Akita University)
Cited by 26
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253